Blind : Actualité Blind en direct - P1 | Bourse Reflex
Accueil > Tags > Blind

  • Toutes les actualités en rapport avec « Blind »

02/05 07:30 Blind - ORAL PRESENTATION OF THERANEXUS AT THE 9TH EUROPEAN CONGRESS ON NARCOLEPSY 5 AND 6 MAY IN MONTPELLIER

26/04 18:00 Blind - THERANEXUS ANNOUNCES ITS 2017 ANNUAL RESULTS AND PRESENTS AN UPDATE ON THE PROGRESS OF ITS CLINICAL TRIALS

26/04 18:00 Blind - THERANEXUS ANNONCE SES RESULTATS ANNUELS 2017 ET PRESENTE UN POINT D'ACTUALITE CONCERNANT L'AVANCEE DE SES ESSAIS CLINIQUES

23/04 07:30 Blind - LE THN102 OBTIENT LE STATUT D'INVESTIGATIONAL NEW DRUG DE LA FOOD AND DRUG ADMINISTRATION (FDA)

23/04 07:30 Blind - THN102 OBTAINS INVESTIGATIONAL NEW DRUG STATUS FROM THE FOOD AND DRUG ADMINISTRATION (FDA)

19/04 18:00 Blind - THERANEXUS ANNOUNCES THE FIRST EUROPEAN APPROVAL FOR ITS PHASE 2 CLINICAL TRIAL WITH THN 102 IN PARKINSON'S DISEASE PATIENTS

19/04 18:00 Blind - THERANEXUS ANNONCE L'OBTENTION D'UNE PREMIERE AUTORISATION EUROPEENNE POUR L'ETUDE CLINIQUE DE PHASE 2 AVEC THN102 DANS LA MALADIE DE PARKINSON

19/06 07:30 Blind - Quantum Genomics details positive results from its Phase IIa trial of QGC001 for the treatment of arterial hypertension

13/12 18:30 Blind - GENTICEL REPORTS FINAL RESULTS OF GTL001 PHASE 2 TRIAL IN HPV16/18-INFECTED WOMEN

13/10 18:00 Blind - Quantum Genomics announces 2016 first-half financial results and first nine months business update

29/09 17:45 Blind - Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension

30/06 18:00 Blind - Quantum Genomics Initiates Phase IIa trial for Heart Failure, the second strategic initiative for its BAPAI therapeutic platform

23/06 17:45 Blind - GENTICEL REPORTS 18 MONTH INTERIM ANALYSIS OF GTL001 PHASE 2 TRIAL IN HPV16/18 INFECTED WOMEN

13/06 18:35 Blind - GENTICEL ANNOUNCES COMPLETION OF TWO MAJOR MILESTONES IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001

01/06 19:00 Blind - GENTICEL ANNOUNCES PUBLICATION IN 'CLINICAL CANCER RESEARCH' OF PHASE 1 TRIAL RESULTS SUPPORTING SAFETY, TOLERABILITY AND IMMUNOGENICITY OF GTL001

28/04 18:35 Blind - BUSINESS UPDATE - FIRST QUARTER 2016

20/04 18:30 Blind - GENTICEL REPORTS ADDITIONAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001

14/03 07:00 Blind - GENTICEL ANNOUNCES 2015 ANNUAL RESULTS AND STRATEGIC UPDATE FOR 2016

27/01 18:40 Blind - GENTICEL REPORTS INITIAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001

07/01 07:30 Blind - GENTICEL TO EVALUATE ROCHE MOLECULAR SYSTEMS' COBAS(R) HPV TEST IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001